Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib, Chidamide, and Rituximab vs R-CHOP in Double-Expressor DLBCL
NCT06890585Phase 2Not yet recruiting
- Start
- Jun 2025
- Primary completion
- Dec 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, tucidinostat in diffuse large B-cell lymphoma (DLBCL). Planned start Jun 2025; status: not yet recruiting.
02
Drugs
zanubrutinibtucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06890585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890585.